PLK2 and Miyoshi myopathy: Overall, this study supports the promising therapeutic strategy with KIRA8 and nilotinib against MM by providing molecular and human pathological evidence regarding MM, as well as the likelihood of PLK2 as a novel therapeutic target and biomarker for MM.